ArticleFrontiers in oncology2022
Pretreatment Metabolic Parameters Measured by
Article in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 19 citations in OpenAlex.
- Nuclear medicine in predicting hepatocellular carcinoma response.Nuclear medicine communications · 2026Review
- Clinical Significance of Intratumoral Contrast Pooling on Contrast-Enhanced CT After Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma.Current oncology (Toronto, Ont.) · 2025Article
- Article
- The Role of Nuclear Medicine in Predicting Treatment Response to Immunotherapy and Targeted Therapy in Hepatocellular Carcinoma: A Narrative Review.Journal of hepatocellular carcinoma · 2025Review
- Biomarkers and prognostic factors of PD-1/PD-L1 inhibitor-based therapy in patients with advanced hepatocellular carcinoma.Biomarker research · 2024Review
- Metabolic parameters of pretreatment 2-[Quantitative imaging in medicine and surgery · 2024Article
- Multiparameter diagnostic model based onBMC cancer · 2023Article
- Metabolic Tumor Volume Measured byJournal of hepatocellular carcinoma · 2023Article
- The role ofFrontiers in immunology · 2023Article
- Multiparameter diagnostic model based onBMC cancer · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: This study aimed to assess the pretreatment Methods: All patients (n=20) underwent pretreatment Results: There was significant difference in TLR (5.59 ± 1.90 vs. 2.84 ± 1.70, respectively; Conclusions: TLR may be a powerful marker to predict PTR of HCC patients with BCLC stage C who were treated with conversion therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.